174 related articles for article (PubMed ID: 31839806)
21. Implications for sequencing of biologic therapy and choice of second anti-TNF in patients with inflammatory bowel disease: results from the IMmunogenicity to Second Anti-TNF therapy (IMSAT) therapeutic drug monitoring study.
Chanchlani N; Lin S; Auth MK; Lee CL; Robbins H; Looi S; Murugesan SV; Riley T; Preston C; Stephenson S; Cardozo W; Sonwalkar SA; Allah-Ditta M; Mansfield L; Durai D; Baker M; London I; London E; Gupta S; Di Mambro A; Murphy A; Gaynor E; Jones KDJ; Claridge A; Sebastian S; Ramachandran S; Selinger CP; Borg-Bartolo SP; Knight P; Sprakes MB; Burton J; Kane P; Lupton S; Fletcher A; Gaya DR; Colbert R; Seenan JP; MacDonald J; Lynch L; McLachlan I; Shields S; Hansen R; Gervais L; Jere M; Akhtar M; Black K; Henderson P; Russell RK; Lees CW; Derikx LAAP; Lockett M; Betteridge F; De Silva A; Hussenbux A; Beckly J; Bendall O; Hart JW; Thomas A; Hamilton B; Gordon C; Chee D; McDonald TJ; Nice R; Parkinson M; Gardner-Thorpe H; Butterworth JR; Javed A; Al-Shakhshir S; Yadagiri R; Maher S; Pollok RCG; Ng T; Appiahene P; Donovan F; Lok J; Chandy R; Jagdish R; Baig D; Mahmood Z; Marsh L; Moss A; Abdulgader A; Kitchin A; Walker GJ; George B; Lim YH; Gulliver J; Bloom S; Theaker H; Carlson S; Cummings JRF; Livingstone R; Beale A; Carter JO; Bell A; Coulter A; Snook J; Stone H; Kennedy NA; Goodhand JR; Ahmad T;
Aliment Pharmacol Ther; 2022 Oct; 56(8):1250-1263. PubMed ID: 36039036
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of the safety and effectiveness after switch from adalimumab originator to biosimilar SB5 in patients with inflammatory bowel disease in a real-life setting.
Deprez N; De Somer T; Baert D; Deceuninck M; Huys I; Mattens V; Sterckx A; Vanderstraeten E; Vandervoort J; Van Heddegem N; Dewint P
Acta Gastroenterol Belg; 2022; 85(4):557-564. PubMed ID: 36566364
[TBL] [Abstract][Full Text] [Related]
23. Interactions Between Thiopurine Metabolites, Adalimumab, and Antibodies Against Adalimumab in Previously Infliximab-Treated Patients with Inflammatory Bowel Disease.
Holmstrøm RB; Mogensen DV; Brynskov J; Ainsworth MA; Nersting J; Schmiegelow K; Steenholdt C
Dig Dis Sci; 2018 Jun; 63(6):1583-1591. PubMed ID: 29564674
[TBL] [Abstract][Full Text] [Related]
24. A SPECIAL MEETING REVIEW EDITION: Clinical Research Highlights in IBD: Diagnosis and Anti-Tumor Necrosis Factor Monitoring: Digestive Disease Week 2013May 18-21, 2013 • Orlando, FloridaSpecial Reporting on:• Serological and Inflammatory IBD Marker Prevalence As Function of Age in a Large Cohort of Patients Presenting IBD-Like Gastrointestinal Symptoms• Prevalence of Antibodies to Adalimumab (ATA) and Correlation Between ATA and Low Serum Drug Concentration on CRP and Clinical Symptoms in a Prospective Sample of IBD Patients• Serum Adalimumab Levels and Antibodies Correlate with Endoscopic Intestinal Inflammation and Inflammatory Markers in Patients with Inflammatory Bowel Disease• Comparison of Early Measurement of Infliximab and Antibodies-to-Infliximab Serum Levels with Standard Trough Analysis• Trough Levels and Antidrug Antibodies Predict Safety and Success of Restarting Infliximab After a Long Drug Holiday• A Multi-Center Observational Study in Community Gastroenterology Practices Evaluating the Clinical Usage of Testing for Serum Levels of Infliximab and Antibodies to Infliximab• Preoperative Serum Biologic Levels Do Not Impact Postoperative Outcomes in Ulcerative Colitis• Higher Preoperative Serum Biologic Levels Are Associated with Postoperative Complications in Crohn's Disease PatientsWith Expert Commentary by: William J. Sandborn, MDProfessor and Chief, Division of GastroenterologyDirector, UCSD IBD CenterUC San Diego Health SystemLa Jolla, California.
Gastroenterol Hepatol (N Y); 2013 Aug; 9(8 Suppl 4):1-16. PubMed ID: 24872794
[No Abstract] [Full Text] [Related]
25. Long-term efficacy, safety, and immunogenicity of the adalimumab biosimilar, PF-06410293, in patients with rheumatoid arthritis after switching from reference adalimumab (Humira®) or continuing biosimilar therapy: week 52-92 data from a randomized, double-blind, phase 3 trial.
Fleischmann RM; Alvarez DF; Bock AE; Cronenberger C; Vranic I; Zhang W; Alten R
Arthritis Res Ther; 2021 Sep; 23(1):248. PubMed ID: 34563243
[TBL] [Abstract][Full Text] [Related]
26. Impact of immunogenicity on efficacy and tolerability of tumour necrosis factor inhibitors: pooled analysis of biosimilar studies in rheumatoid arthritis.
Emery P; Suh CH; Weinblatt ME; Smolen JS; Keystone EC; Genovese M; Vencovsky J; Kay J; Hong E; Baek Y; Ghil J
Scand J Rheumatol; 2020 Sep; 49(5):361-370. PubMed ID: 32468892
[No Abstract] [Full Text] [Related]
27. Biosimilars of adalimumab: the upcoming challenge in IBD.
Fiorino G; Gilardi D; Correale C; Furfaro F; Roda G; Loy L; Argollo M; Allocca M; Peyrin-Biroulet L; Danese S
Expert Opin Biol Ther; 2019 Oct; 19(10):1023-1030. PubMed ID: 30601098
[No Abstract] [Full Text] [Related]
28. Proteolytic cleavage and loss of function of biologic agents that neutralize tumor necrosis factor in the mucosa of patients with inflammatory bowel disease.
Biancheri P; Brezski RJ; Di Sabatino A; Greenplate AR; Soring KL; Corazza GR; Kok KB; Rovedatti L; Vossenkämper A; Ahmad N; Snoek SA; Vermeire S; Rutgeerts P; Jordan RE; MacDonald TT
Gastroenterology; 2015 Nov; 149(6):1564-1574.e3. PubMed ID: 26170138
[TBL] [Abstract][Full Text] [Related]
29. High Anti-Infliximab Antibody Titers Do Not Impact Response to Subsequent Adalimumab Treatment in Inflammatory Bowel Diseases.
Sasson AN; Ananthakrishnan AN
Dig Dis Sci; 2022 Jul; 67(7):3124-3128. PubMed ID: 34117949
[TBL] [Abstract][Full Text] [Related]
30. Full Interchangeability in Regard to Immunogenicity Between the Infliximab Reference Biologic and Biosimilars CT-P13 and SB2 in Inflammatory Bowel Disease.
Fiorino G; Ruiz-Argüello MB; Maguregui A; Nagore D; Correale C; Radice S; Gilardi D; Allocca M; Furfaro F; Martínez A; Danese S
Inflamm Bowel Dis; 2018 Feb; 24(3):601-606. PubMed ID: 29462398
[TBL] [Abstract][Full Text] [Related]
31. Review article: pharmacological aspects of anti-TNF biosimilars in inflammatory bowel diseases.
Papamichael K; Van Stappen T; Jairath V; Gecse K; Khanna R; D'Haens G; Vermeire S; Gils A; Feagan BG; Levesque BG; Vande Casteele N
Aliment Pharmacol Ther; 2015 Nov; 42(10):1158-69. PubMed ID: 26365281
[TBL] [Abstract][Full Text] [Related]
32. Response to Biologic Drugs in Patients With Rheumatoid Arthritis and Antidrug Antibodies.
Bitoun S; Hässler S; Ternant D; Szely N; Gleizes A; Richez C; Soubrier M; Avouac J; Brocq O; Sellam J; de Vries N; Huizinga TWJ; Jury EC; Manson JJ; Mauri C; Matucci A; Hacein Bey Abina S; Mulleman D; Pallardy M; Broët P; Mariette X;
JAMA Netw Open; 2023 Jul; 6(7):e2323098. PubMed ID: 37436748
[TBL] [Abstract][Full Text] [Related]
33. Drug immunogenicity in patients with inflammatory arthritis and secondary failure to tumour necrosis factor inhibitor therapies: the REASON study.
Balsa A; Sanmarti R; Rosas J; Martin V; Cabez A; Gómez S; Montoro M
Rheumatology (Oxford); 2018 Apr; 57(4):688-693. PubMed ID: 29365183
[TBL] [Abstract][Full Text] [Related]
34. Adalimumab Biosimilars in the Treatment of Rheumatoid Arthritis: A Systematic Review of the Evidence for Biosimilarity.
Huizinga TWJ; Torii Y; Muniz R
Rheumatol Ther; 2021 Mar; 8(1):41-61. PubMed ID: 33263165
[TBL] [Abstract][Full Text] [Related]
35. Glycan and Peptide IgE Epitopes of the TNF-alpha Blockers Infliximab and Adalimumab - Precision Diagnostics by Cross-Reactivity Immune Profiling of Patient Sera.
Homann A; Röckendorf N; Kromminga A; Frey A; Platts-Mills TA; Jappe U
Theranostics; 2017; 7(19):4699-4709. PubMed ID: 29187897
[TBL] [Abstract][Full Text] [Related]
36. Development of an ELISA-Based Competitive Binding Assay for the Analysis of Drug Concentration and Antidrug Antibody Levels in Patients Receiving Adalimumab or Infliximab.
Hock BD; Stamp LK; Hayman MW; Keating PE; Helms ET; Barclay ML
Ther Drug Monit; 2016 Feb; 38(1):32-41. PubMed ID: 26222874
[TBL] [Abstract][Full Text] [Related]
37. Ashkenazi Jewish origin protects against formation of antibodies to infliximab and therapy failure.
Ungar B; Haj-Natour O; Kopylov U; Yavzori M; Fudim E; Picard O; Loebstein R; Lahat A; Maor Y; Avidan B; Lang A; Weiss B; Chowers Y; Eliakim R; Ben-Horin S
Medicine (Baltimore); 2015 May; 94(18):e673. PubMed ID: 25950682
[TBL] [Abstract][Full Text] [Related]
38. Biosimilars of Adalimumab in Inflammatory Bowel Disease: Are we Ready for that?
Argollo M; Fiorino G; Gilardi D; Furfaro F; Roda G; Loy L; Allocca M; Peyrin-Biroulet L; Danese S
Curr Pharm Des; 2019; 25(1):7-12. PubMed ID: 30864505
[TBL] [Abstract][Full Text] [Related]
39. The decline of anti-drug antibody titres after discontinuation of anti-TNFs: implications for predicting re-induction outcome in IBD.
Ben-Horin S; Mazor Y; Yanai H; Ron Y; Kopylov U; Yavzori M; Picard O; Fudim E; Maor Y; Lahat A; Coscas D; Eliakim R; Dotan I; Chowers Y
Aliment Pharmacol Ther; 2012 Mar; 35(6):714-22. PubMed ID: 22288419
[TBL] [Abstract][Full Text] [Related]
40. A propensity score-weighted comparison between adalimumab originator and its biosimilars, ABP501 and SB5, in inflammatory bowel disease: a multicenter Italian study.
Barberio B; Cingolani L; Canova C; Barbieri G; Sablich R; Urbano MT; Bertani L; Costa F; Bodini G; Demarzo MG; Ferronato A; Buda A; Melatti P; Massimi D; Savarino EV; Zingone F
Therap Adv Gastroenterol; 2021; 14():17562848211031420. PubMed ID: 34349836
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
